Comparison of cilostazol and clopidogrel after successful coronary stenting

Seung Whan Lee; Seong Wook Park; Myeong Ki Hong; Cheol Whan Lee; Young Hak Kim; Jae Hyeong Park; Su Jin Kang; Ki Hoon Han; Jae Joong Kim; Seung Jung Park

doi:10.1016/j.amjcard.2004.12.012

Comparison of cilostazol and clopidogrel after successful coronary stenting

Seung Whan Lee, Seong Wook Park, Myeong Ki Hong, Cheol Whan Lee, Young Hak Kim, Jae Hyeong Park, Su Jin Kang, Ki Hoon Han, Jae Joong Kim, Seung Jung Park

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

67 Citations (Scopus)

Abstract

This study compared the safety and efficacy of cilostazol and clopidogrel after coronary stenting. Patients (n = 689) who underwent successful stenting were randomly assigned to receive cilostazol (group 1, n = 344, 612 lesions) or clopidogrel (group 2, n = 345, 628 lesions). The incidence of subacute stent thrombosis or major adverse cardiac events, including death, myocardial infarction, and target lesion revascularization within 30 days (2.6% in group 1 vs 2.0% in group 2, p = 0.61) and side effects that required cessation of study drug (0.6% each) did not differ statistically between groups. These results indicate that cilostazol is as safe and effective as clopidogrel in preventing thrombotic complications after stenting.

Original language	English
Pages (from-to)	859-862
Number of pages	4
Journal	American Journal of Cardiology
Volume	95
Issue number	7
DOIs	https://doi.org/10.1016/j.amjcard.2004.12.012
Publication status	Published - 2005 Apr 1

All Science Journal Classification (ASJC) codes

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.amjcard.2004.12.012

Cite this

@article{fee23464925d487e96dec49f6090f6d4,

title = "Comparison of cilostazol and clopidogrel after successful coronary stenting",

abstract = "This study compared the safety and efficacy of cilostazol and clopidogrel after coronary stenting. Patients (n = 689) who underwent successful stenting were randomly assigned to receive cilostazol (group 1, n = 344, 612 lesions) or clopidogrel (group 2, n = 345, 628 lesions). The incidence of subacute stent thrombosis or major adverse cardiac events, including death, myocardial infarction, and target lesion revascularization within 30 days (2.6% in group 1 vs 2.0% in group 2, p = 0.61) and side effects that required cessation of study drug (0.6% each) did not differ statistically between groups. These results indicate that cilostazol is as safe and effective as clopidogrel in preventing thrombotic complications after stenting.",

author = "Lee, {Seung Whan} and Park, {Seong Wook} and Hong, {Myeong Ki} and Lee, {Cheol Whan} and Kim, {Young Hak} and Park, {Jae Hyeong} and Kang, {Su Jin} and Han, {Ki Hoon} and Kim, {Jae Joong} and Park, {Seung Jung}",

year = "2005",

month = apr,

day = "1",

doi = "10.1016/j.amjcard.2004.12.012",

language = "English",

volume = "95",

pages = "859--862",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Comparison of cilostazol and clopidogrel after successful coronary stenting

AU - Lee, Seung Whan

AU - Park, Seong Wook

AU - Hong, Myeong Ki

AU - Lee, Cheol Whan

AU - Kim, Young Hak

AU - Park, Jae Hyeong

AU - Kang, Su Jin

AU - Han, Ki Hoon

AU - Kim, Jae Joong

AU - Park, Seung Jung

PY - 2005/4/1

Y1 - 2005/4/1

N2 - This study compared the safety and efficacy of cilostazol and clopidogrel after coronary stenting. Patients (n = 689) who underwent successful stenting were randomly assigned to receive cilostazol (group 1, n = 344, 612 lesions) or clopidogrel (group 2, n = 345, 628 lesions). The incidence of subacute stent thrombosis or major adverse cardiac events, including death, myocardial infarction, and target lesion revascularization within 30 days (2.6% in group 1 vs 2.0% in group 2, p = 0.61) and side effects that required cessation of study drug (0.6% each) did not differ statistically between groups. These results indicate that cilostazol is as safe and effective as clopidogrel in preventing thrombotic complications after stenting.

AB - This study compared the safety and efficacy of cilostazol and clopidogrel after coronary stenting. Patients (n = 689) who underwent successful stenting were randomly assigned to receive cilostazol (group 1, n = 344, 612 lesions) or clopidogrel (group 2, n = 345, 628 lesions). The incidence of subacute stent thrombosis or major adverse cardiac events, including death, myocardial infarction, and target lesion revascularization within 30 days (2.6% in group 1 vs 2.0% in group 2, p = 0.61) and side effects that required cessation of study drug (0.6% each) did not differ statistically between groups. These results indicate that cilostazol is as safe and effective as clopidogrel in preventing thrombotic complications after stenting.

UR - http://www.scopus.com/inward/record.url?scp=15244356877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15244356877&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2004.12.012

DO - 10.1016/j.amjcard.2004.12.012

M3 - Article

C2 - 15781016

AN - SCOPUS:15244356877

SN - 0002-9149

VL - 95

SP - 859

EP - 862

JO - American Journal of Cardiology

JF - American Journal of Cardiology

IS - 7

ER -

Comparison of cilostazol and clopidogrel after successful coronary stenting

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this